CompanyMGXNasdaqEmeryville, CA

Metagenomi Therapeutics, Inc.

Metagenomi Therapeutics develops in vivo CRISPR gene-editing tools for genetic diseases.

SEC EDGAR ClinicalTrials.gov metagenomi.co

8-KSep 22Latest SEC filing, period to Sep 21

Aug 10Latest story

August 2026

Metagenomi reports Q2 2026 results, stays on track for MGX-001 hemophilia A IND filing

Aug 10Quarterly updateMetagenomi Therapeutics, Inc.